Literature DB >> 18976029

The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran.

Raika Jamali1, Akram Pourshams, Sedighe Amini, Mohammad-Reza Deyhim, Houri Rezvan, Reza Malekzadeh.   

Abstract

BACKGROUND: The objective of this study was to determine the upper normal limit of serum alanine aminotransferase level in a population-based study in Golestan Province, northeast Iran.
METHODS: From the randomly invited individuals (2,292), 698 out of the 916 males and 1,351 out of the 1,376 females participated in the study (participation rate: 76.2% and 98.1%, respectively). One hundred and twenty-one participants were excluded due to positive hepatitis B surface antigen or hepatitis C virus antibody and/or drinking more than 20 grams of alcohol per day. A total of 1,928 participants (1300 females) were included. The upper normal limit of serum alanine aminotransferase level was defined as the 95th percentile.
RESULTS: The upper normal limit of serum alanine aminotransferase level in normal weight and nondiabetics was significantly lower than the total study group (36 versus 45 U/L). Serum alanine aminotransferase level was independently associated with male gender, body mass index, and diabetes mellitus (OR=2.05; 95%CI: 1.44 - 2.94, OR=2.76; 95%CI: 1.84 - 4.13, and OR=2.96; 95%CI: 1.56 - 5.61, respectively).
CONCLUSION: Considering the lower calculated upper normal limit in normal weight nondiabetic participants in this study, we recommend setting new upper normal limit for serum alanine aminotransferase level. It seems reasonable to set upper normal limit for serum alanine aminotransferase level in males and females separately.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976029

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  23 in total

1.  Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

Authors:  Raika Jamali; Mohsen Razavizade; Abbas Arj; Mohammad Hossein Aarabi
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  Upper limits of normal for alanine aminotransferase activity in the United States population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

3.  Determination of the upper cut-off values of serum alanine aminotransferase and aspartate aminotransferase in Chinese.

Authors:  Peng Zhang; Chun-Yan Wang; Yu-Xiang Li; Yu Pan; Jun-Qi Niu; Shu-Mei He
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 4.  The gastro-esophageal malignancies in Northern Iran research project: impact on the health research and health care systems in Iran.

Authors:  Sadaf G Sepanlou; Arash Etemadi; Farin Kamangar; Alireza Sepehr; Akram Pourshams; Hossein Poustchi; Farhad Islami; Alireza Sadjadi; Dariush Nasrollahzadeh; Shahryar Semnani; Farrokh Saidi; Christian C Abnet; Bruce Ponder; Paul D Pharoah; Nicholas E Day; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Reza Malekzadeh
Journal:  Arch Iran Med       Date:  2013-01       Impact factor: 1.354

5.  Should we rely on the findings of each published randomized controlled study?

Authors:  Ali Kabir
Journal:  Hepat Mon       Date:  2013-03-14       Impact factor: 0.660

6.  Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease.

Authors:  Ghobad Abangah; Atefeh Yousefi; Rouhangiz Asadollahi; Yousef Veisani; Paria Rahimifar; Sajjad Alizadeh
Journal:  Iran Red Crescent Med J       Date:  2014-01-05       Impact factor: 0.611

7.  First National Report on Aminotransaminases' Percentiles in Children of the Middle East and North Africa (MENA): the CASPIAN-III Study.

Authors:  Roya Kelishadi; Seyed-Hossein Abtahi; Mostafa Qorbani; Ramin Heshmat; Mohammad Esmaeil Motlagh; Mahnaz Taslimi; Tahereh Aminaee; Gelayol Ardalan; Parinaz Poursafa; Payam Moin
Journal:  Hepat Mon       Date:  2012-11-30       Impact factor: 0.660

8.  The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial.

Authors:  Mohsen Razavizade; Raika Jamali; Abbas Arj; Seyyed Mohammad Matini; Alireza Moraveji; Effat Taherkhani
Journal:  Hepat Mon       Date:  2013-05-21       Impact factor: 0.660

9.  Alanine aminotransferase elevation in obese infants and children: a marker of early onset non alcoholic Fatty liver disease.

Authors:  Guido Engelmann; Georg Friedrich Hoffmann; Juergen Grulich-Henn; Ulrike Teufel
Journal:  Hepat Mon       Date:  2014-04-07       Impact factor: 0.660

10.  Normal limit for serum alanine aminotransferase level and distribution of metabolic factors in old population of kalaleh, iran.

Authors:  Ali Kabir; Akram Pourshams; Masoud Khoshnia; Fatemeh Malekzadeh
Journal:  Hepat Mon       Date:  2013-10-20       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.